Switching between reference adalimumab and biosimilars in chronic immune‐mediated inflammatory diseases: A systematic literature review-Reference-Cited by-同舟云学术

Switching between reference adalimumab and biosimilars in chronic immune‐mediated inflammatory diseases: A systematic literature review

Published:2021-11-02 Issue: Volume: Page:
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

García‐Beloso Nerea¹^ORCID,Altabás‐González Irene²³,Samartín‐Ucha Marisol¹³,Gayoso‐Rey Mónica¹,De Castro‐Parga María Luísa⁴,Salgado‐Barreira Ángel⁵,Cibeira‐Badia Amelia⁶,Piñeiro‐Corrales María Guadalupe¹,González‐Vilas Daniel⁷,Pego‐Reigosa Jose María²³,Martínez‐López de Castro Noemí¹³

Affiliation:

1. Department of Pharmacy University Hospital Complex of Vigo Vigo Spain

2. Department of Rheumatology University Hospital Complex of Vigo Vigo Spain

3. IRIDIS (Investigation in Rheumatology and Immune‐Mediated Diseases) Group Galicia Sur Health Research Institute, SERGAS‐UVIGO Vigo Spain

4. Department of Digestive University Hospital Complex of Vigo Vigo Spain

5. Methodology and Statistics Unit Galicia Sur Health Research Institute (IIS Galicia Sur, SERGAS‐UVIGO Vigo Spain

6. Department of Scientific Library University Hospital Complex of Vigo Vigo Spain

7. Department of Dermatology University Hospital Complex of Vigo Vigo Spain

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15101

Reference54 articles.

1. European Medicines Agency (EMA).Guidelines on similar biological medicinal products. Accessed December 7 2019.http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf

2. US Food and Drug Administration.Guidance for Industry: Scientific considerations in demonstrating biosimilarity to a reference product. Rockville MD: US Food and Drug Administration; 2015. Accessed December 28 2020.https://www.fda.gov/media/82647/download

3. Biosimilar switching—current state of knowledge;Wiland P;Reumatologia,2018

4. Biosimilars in the EU: information guide for health professionals.2019. Accessed October 24 2020.https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf

5. Humira® (adalimumab).Information from the EMA. Accessed October 24 2020.https://www.ema.europa.eu/en/medicines/human/EPAR/humira

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease;Journal of Clinical Medicine;2023-10-29

2. Biosimilars in the treatment of rheumatoid arthritis: a pharmacokinetic overview;Expert Opinion on Drug Metabolism & Toxicology;2023-10-25

3. The role of inflammation in autoimmune disease: a therapeutic target;Frontiers in Immunology;2023-10-04

4. Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus;Journal of Clinical Medicine;2023-10-03

5. Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast];Open Access Rheumatology: Research and Reviews;2023-10